Boosted CAR-T Cells Tackle Cancer with Less Dose
Novel Intracellular Immune Checkpoints for T Cell Therapy
Tags: Monash University, Australia, Healthcare & Lifesciences
The technology identifies PTPN2 and PTPN1 in T cells as key targets for enhancing CD8 T cell therapy, drastically improving solid tumour inhibition. Inhibiting both targets in CAR T cells eradicated solid tumours in a mouse model of breast cancer with minimal T cell doses. Applications include requiring lower T cell doses, improved tumour infiltration, overcoming T cell exhaustion, and providing a safer, more effective alternative to conventional immune checkpoints. This innovation also allows for gene deletion or small molecule inhibition approaches. Patents have been filed in multiple jurisdictions, evidencing its novelty and potential for widespread application.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
